Folate receptor-mediated drug targeting: From therapeutics to diagnostics

Journal of Pharmaceutical Sciences

Volumn 94, Issue 10, 2005, Pages 2135-2146

  Hilgenbrink, Andrew R ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Arthritis; Cancer chemotherapy; Folate conjugate; Folate receptor; Imaging methods; Inflammatory disease; Liposomes; Nano particles; Targeted drug delivery

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD28 ANTIBODY; CONTRAST MEDIUM; CYTOTOXIC AGENT; EC 72; FOLATE CD28 ANTIBODY CONJUGATE; FOLATE PLUS MAYTANSINOID; FOLATE PLUS MITOMYCIN C; FOLATE RECEPTOR; FOLIC ACID; IMATINIB; IMMUNOSTIMULATING AGENT; LIPOSOME; MACROGOL; MITOMYCIN C; NEW DRUG; PSEUDOMONAS EXOTOXIN; T CELL RECEPTOR ANTIBODY; TECHNETIUM 99M; TOXIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BINDING AFFINITY; CANCER; CELL SURFACE; DIAGNOSTIC TEST; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; INFLAMMATION; MOLECULAR SIZE; NONHUMAN; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 27944455140     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20457     Document Type: Short Survey

References (136)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831.
2. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70.
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
4. Antony AC. 1992. The biological chemistry of folate receptors. Blood 79:2807-2820.
5. Kamen BA, Capdevila A. 1986. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 83:5983-5987.
6. Antony AC, Kane MA, Portillo RM, Elwood PC, Kolhouse JF. 1985. Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem 260:14911-14917.
7. Leamon CP, Low PS. 1991. Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 88:5572-5576.
8. Wileman T, Harding C, Stahl P. 1985. Receptor-mediated endocytosis. Biochem J 232:1-14.
9. Lee RJ, Wang S, Low PS. 1996. Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim Biophys Acta 1312:237-242.
10. Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. 2004. Ligand binding and kinetics of folate receptor recycling in vivo: Impact on receptor-mediated drug delivery. Mol Pharmacol 66:1406-1414.
11. Turek JJ, Leamon CP, Low PS. 1993. Endocytosis of folate-protein conjugates: Ultrastructural localization in KB cells. J Cell Sci 106:423-430.
12. Mattes MJ, Major PP, Goldenberg DM, Dion AS, Hutter RV, Klein KM. 1990. Patterns of antigen distribution in human carcinomas. Cancer Res 50:880s-884s.
13. Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, Zurawski VR, Jr. 1991. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 51:6125-6132.
14. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Jr., Kamen BA. 1992. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396-3401.
15. Ross JF, Chaudhuri PK, Ratnam M. 1994. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73:2432-2443.
16. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. 1992. Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. Cancer Res 52:6708-6711.
17. Weitman SD, Frazier KM, Kamen BA. 1994. The folate receptor in central nervous system malignancies of childhood. J Neurooncol 21:107-112.
18. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Jr., Old LJ, Rettig WJ. 1993. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 142:557-567.
19. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. 1997. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193-198.
20. Holm J, Hansen SI, Hoier-Madsen M, Bostad L. 1991. High-affinity folate binding in human choroid plexus. Characterization of radioligand binding, immunoreactivity, molecular heterogeneity and hydrophobic domain of the binding protein. Biochem J 280:267-271.
21. Shen F, Ross JF, Wang X, Ratnam M. 1994. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33:1209-1215.
22. Sadasivan E, Rothenberg SP, da Costa M, Brink L. 1986. Characterization of multiple forms of folate-binding protein from human leukemia cells. Biochim Biophys Acta 882:311-321.
23. Sadasivan E, da Costa M, Rothenberg SP, Brink L. 1987. Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cells. Biochim Biophys Acta 925:36-47.
24. Morikawa J, Li H, Kim S, Nishi K, Ueno S, Suh E, Dougherty E, Shmulevich I, Shiku H, Zhang W, Kobayashi T. 2003. Identification of signature genes by microarray for acute myeloid leukemia without maturation and acute promyelocytic leukemia with t(15;17)(q22;q12)(PML/RARalpha). Int J Oncol 23:617-625.
25. Hartmann LC, Lingle WL, Christianson TJH, Keeney GL, Murphy LM, Hillman D, Oberg AL, Low PS (Manuscript Submitted). Folate receptor overexpression is associated with poor outcome in breast cancer. J Clin Oncology.
26. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Tsukano M, Ratnam M, Matsuyama T. 1999. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42:1609-1616.
27. Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, Low PS. 2002. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 46:1947-1955.
28. Ma Y, Pope RM. 2005. The role of macrophages in rheumatoid arthritis. Curr Pharm Des 11:569-580.
29. Boyle JJ. 2005. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 3:63-68.
30. Cutolo M. 1999. Macrophages as effectors of the immunoendocrinologic interactions in autoimmune rheumatic diseases. Ann N Y Acad Sci 876:32-41; discussion 41-32.
31. Gross V, Andus T, Leser HG, Roth M, Scholmerich J. 1991. Inflammatory mediators in chronic inflammatory bowel diseases. Klin Wochenschr 69:981-987.
32. Schubert C, Christophers E. 1985. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 277:352-358.
33. Christophers E, Mrowietz U. 1995. The inflammatory infiltrate in psoriasis. Clin Dermatol 13:131-135.
34. Hancock WW. 1997. Delayed xenograft rejection. World J Surg 21:917-923.
35. Kennedy MD, Jallad KN, Lu J, Low PS, Ben-Amotz D. 2003. Evaluation of folate conjugate uptake and transport by the choroid plexus of mice. Pharm Res 20:714-719.
36. Patrick TA, Kranz DM, van Dyke TA, Roy EJ. 1997. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. J Neurooncol 32:111-123.
37. Zimmerman J. 1990. Folic acid transport in organ-cultured mucosa of human intestine. Evidence for distinct carriers. Gastroenterology 99:964-972.
38. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. 2004. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol 287:C517-C526.
39. Low PS, Antony AC. 2004. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 56:1055-1058.
40. Lu Y, Low PS. 2002. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675-693.
41. Panwar P, Srivastava V, Tandon V, Mishra P, Chuttani K, Sharma RK, Chandra R, Mishra AK. 2004. (99m)Tc-Tetraethylenepentamine-folate-A new (99m)Tc-based folate derivative for the detection of folate receptor positive tumors: Synthesis and biological evaluation. Cancer Biol Ther 3:995-1001.
42. Ward CM, Acheson N, Seymour LW. 2000. Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients. J Drug Target 8:119-123.
43. Lu JY, Lowe DA, Kennedy MD, Low PS. 1999. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Target 7:43-53.
44. Leamon CP, Low PS. 1992. Cytotoxicity of momordin-folate conjugates in cultured human cells. J Biol Chem 267:24966-24971.
45. Leamon CP, Pastan I, Low PS. 1993. Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem 268:24847-24854.
46. Leamon CP, Low PS. 1994. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target 2:101-112.
47. Atkinson SF, Bettinger T, Seymour LW, Behr JP, Ward CM. 2001. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J Biol Chem 276:27930-27935.
48. Ladino CA, Chari RV, Bourret LA, Kedersha NL, Goldmacher VS. 1997. Folate-maytansinoids: Target-selective drugs of low molecular weight. Int J Cancer 73:859-864.
49. Steinberg G, Borch RF. 2001. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. J Med Chem 44:69-73.
50. Leamon CP, Reddy JA. 2004. Folate-targeted chemotherapy. Adv Drug Deliv Rev 56:1127-1141.
51. Paranjpe PV, Chen Y, Kholodovych V, Welsh W, Stein S, Sinko PJ. 2004. Tumor-targeted bioconjugate based delivery of camptothecin: Design, synthesis and in vitro evaluation. J Control Release 100:275-292.
52. Roy EJ, Gawlick U, Orr BA, Kranz DM. 2004. Folate-mediated targeting of T cells to tumors. Adv Drug Deliv Rev 56:1219-1231.
53. Lu Y, Sega E, Leamon CP, Low PS. 2004. Folate receptor-targeted immunotherapy of cancer: Mechanism and therapeutic potential. Adv Drug Deliv Rev 56:1161-1176.
54. Lu Y, Low PS. 2002. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51:153-162.
55. Lu Y, Low PS. 2003. Immunotherapy of folate receptor-expressing tumors: Review of recent advances and future prospects. J Control Release 91:17-29.
56. Paulos CM, Turk MJ, Breur GJ, Low PS. 2004. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 56:1205-1217.
57. Gawlick U, Kranz DM, Schepkin VD, Roy EJ. 2004. A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. Bioconjug Chem 15:1137-1145.
58. Kranz DM, Patrick TA, Brigle KE, Spinella MJ, Roy EJ. 1995. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc Natl Acad Sci USA 92:9057-9061.
59. Cho BK, Roy EJ, Patrick TA, Kranz DM. 1997. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjug Chem 8:338-346.
60. Kranz DM, Manning TC, Rund LA, Cho BK, Gruber MM, Roy EJ. 1998. Targeting tumor cells with bispecific antibodies and T cells. J Control Release 53:77-84.
61. Patrick TA, Kranz DM, Zachary JF, Roy EJ. 1998. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Int J Cancer 78:470-479.
62. Roy EJ, Cho BK, Rund LA, Patrick TA, Kranz DM. 1998. Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. Int J Cancer 76:761-766.
63. Anderson KE, Eliot LA, Stevenson BR, Rogers JA. 2001. Formulation and evaluation of a folk acid receptor-targeted oral vancomycin liposomal dosage form. Pharm Res 18:316-322.
64. Lee RJ, Low PS. 1994. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198-3204.
65. Lee RJ, Low PS. 1995. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134-144.
66. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. 2002. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594-602.
67. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. 2004. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177-1192.
68. Park EK, Lee SB, Lee YM. 2005. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 26:1053-1061.
69. Hattori Y, Maitani Y. 2004. Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release 97:173-183.
70. Yoo HS, Park TG. 2004. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 100:247-256.
71. Nayak S, Lee H, Chmielewski J, Lyon LA. 2004. Folate-mediated cell targeting and cytotoxicity using thermoresponsive microgels. J Am Chem Soc 126:10258-10259.
72. Yoo HS, Park TG. 2004. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 96:273-283.
73. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, Baker JR, Jr. 2002. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19:1310-1316.
74. Pan D, Turner JL, Wooley KL. 2003. Folic acid-conjugated nanostructured materials designed for cancer cell targeting. Chem Commun (Camb): 2400-2401.
75. Choi H, Choi SR, Zhou R, Kung HF, Chen I. 2004. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 11:996-1004.
76. Salmaso S, Semenzato A, Caliceti P, Hoebeke J, Sonvico F, Dubernet C, Couvreur P. 2004. Specific antitumor targetable beta-cyclodextrin-poly(ethylene glycol)-folic acid drug delivery bioconjugate. Bioconjug Chem 15:997-1004.
77. Caliceti P, Salmaso S, Semenzato A, Carofiglio T, Fornasier R, Fermeglia M, Ferrone M, Pricl S. 2003. Synthesis and physicochemical characterization of folate-cyclodextrin bioconjugate for active drug delivery. Bioconjug Chem 14:899-908.
78. Hwang J, Fitzgerald DJ, Adhya S, Pastan I. 1987. Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48:129-136.
79. Reddy JA, Low PS. 1998. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 15:587-627.
80. Lee JW, Lu JY, Low PS, Fuchs PL. 2002. Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. Bioorg Med Chem 10:2397-2414.
81. Aronov O, Horowitz AT, Gabizon A, Gibson D. 2003. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug Chem 14:563-574.
82. Liu J, Kolar C, Lawson TA, Gmeiner WH. 2001. Targeted drug delivery to chemoresistant cells: Folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J Org Chem 66:5655-5663.
83. Neville DM, Jr., Srinivasachar K, Stone R, Scharff J. 1989. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J Biol Chem 264:14653-14661.
84. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I. 2002. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13:47-58.
85. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. 2005. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293.
86. Leamon CP, Low PS. 2001. Folate-mediated targeting: From diagnostics to drug and gene delivery. Drug Discov Today 6:44-51.
87. Lu Y, Sega E, Low PS. 2005. Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer 116:710-719.
88. Rund LA, Cho BK, Manning TC, Holler PD, Roy EJ, Kranz DM. 1999. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int J Cancer 83:141-149.
89. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. 2000. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6:1949-1957.
90. Ni S, Stephenson SM, Lee RJ. 2002. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 22:2131-2135.
91. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. 2003. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 92:49-67.
92. Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP. 2002. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 9:1542-1550.
93. Reddy JA, Dean D, Kennedy MD, Low PS. 1999. Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J Pharm Sci 88:1112-1118.
94. Lee RJ, Huang L. 1996. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem 271:8481-8487.
95. Zhao XB, Lee RJ. 2004. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 56:1193-1204.
96. Shi G, Guo W, Stephenson SM, Lee RJ. 2002. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J Control Release 80:309-319.
97. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. 1995. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci USA 92:3318-3322.
98. Pan XQ, Wang H, Shukla S, Sekido M, Adams DM, Tjarks W, Barth RF, Lee RJ. 2002. Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy. Bioconjug Chem 13:435-442.
99. Pan XQ, Wang H, Lee RJ. 2002. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res 22:1629-1633.
100. Sudimack JJ, Adams D, Rotaru J, Shukla S, Yan J, Sekido M, Barth RF, Tjarks W, Lee RJ. 2002. Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy. Pharm Res 19:1502-1508.
101. Carlsson J, Kullberg EB, Capala J, Sjoberg S, Edwards K, Gedda L. 2003. Ligand liposomes and boron neutron capture therapy. J Neurooncol 62:47-59.
102. Stephenson SM, Yang W, Stevens PJ, Tjarks W, Barth RF, Lee RJ. 2003. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res 23:3341-3345.
103. Henriksen G, Schoultz BW, Michaelsen TE, Bruland OS, Larsen RH. 2004. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol 31:441-449.
104. Turk MJ, Waters DJ, Low PS. 2004. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 213:165-172.
105. Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 42:419-436.
106. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. 1997. Long-circulating liposomes for drug delivery in cancer therapy: A review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 24:337-344.
107. Papahadjopoulos D. 1995. Stealth liposomes, ed. Boca Raton: CRC Press, pp 1-6.
108. Gabizon A, Papahadjopoulos D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949-6953.
109. Gabizon AA. 2001. Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet. Clin Cancer Res 7:223-225.
110. Gabizon A, Horowitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, Qazen MM, Zalipsky S. 1999. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies. Bioconjug Chem 10: 289-298.
111. Lee RJ, Wang S, Turk MJ, Low PS. 1998. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep 18:69-78.
112. Slepushkin VA, Simoes S, Dazin P, Newman MS, Guo LS, Pedroso de Lima MC, Duzgunes N. 1997. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J Biol Chem 272:2382-2388.
113. Litzinger DC, Huang L. 1992. Phosphatidylethanolamine liposomes: Drug delivery, gene transfer and immunodiagnostic applications. Biochim Biophys Acta 1113:201-227.
114. Tolstikov W, Cole R, Fang H, Pincus SH. 1997. Influence of endosome-destabilizing peptides on efficacy of anti-HIV immunotoxins. Bioconjug Chem 8:38-43.
115. Glushakova SE, Omelyanenko VG, Lukashevitch IS, Bogdanov AA, Jr., Moshnikova AB, Kozytch AT, Torchilin VP. 1992. The fusion of artificial lipid membranes induced by the synthetic arena-virus 'fusion peptide'. Biochim Biophys Acta 1110:202-208.
116. Jiricek R, Schwarz G, Stegmann T. 1997. Pores formed by influenza hemagglutinin. Biochim Biophys Acta 1330:17-28.
117. Turk MJ, Reddy JA, Chmielewski JA, Low PS. 2002. Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim Biophys Acta 1559:56-68.
118. Reddy JA, Low PS. 2000. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release 64:27-37.
119. Mathias CJ, Wang S, Low PS, Waters DJ, Green MA. 1999. Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl Med Biol 26:23-25.
120. Wang S, Luo J, Lantrip DA, Waters DJ, Mathias CJ, Green MA, Fuchs PL, Low PS. 1997. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug Chem 8:673-679.
121. Wang S, Lee RJ, Mathias CJ, Green MA, Low PS. 1996. Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine-Folate, a potential radiopharmaceutical for tumor imaging. Bioconjug Chem 7:56-62.
122. Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, Douglas N. 2002. Synthesis and biological evaluation of EC20: A new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug Chem 13:1200-1210.
123. Ke C, Mathias CJ, Green MA. 2003. The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol 30:811-817.
124. Ilgan S, Yang DJ, Higuchi T, Zareneyrizi F, Bayhan H, Yu D, Kim EE, Podoloff DA. 1998. 99mTc-ethylenedicysteine-folate: A new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother Radiopharm 13:427-435.
125. Kulkarni PV, Antich PP, Constantinescu A, Prior JO, Nguyen T, Fernando J, Anderson JA, Weitman SD, Kamen BA, Parkey RW, Chaney RC, Fenyves BA. 1995. Folate receptor imaging with I-125 labeled folic acid with a whole body small animal imaging device built with plastic scintillating optical. Nucl Instr and Methods in Phys Res B 99:800-803.
126. Guo W, Hinkle GH, Lee RJ. 1999. 99mTc-HYNIC-folate: A novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 40:1563-1569.
127. Moon WK, Lin Y, O'Loughlin T, Tang Y, Kim DE, Weissleder R, Tung CH. 2003. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug Chem 14:539-545.
128. Tung CH, Lin Y, Moon WK, Weissleder R. 2002. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochem 3:784-786.
129. Kennedy MD, Jallad KN, Thompson DH, Ben-Amotz D, Low PS. 2003. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 8:636-641.
130. Barry NP, Bower A, Konda SD, Singha A, Wiener EC, Gratton EE. 2001. Near infrared contrast agent for tumor cells expressing the high affinity folate receptor. Biophys J 80:656.639.
131. Konda SD, Wang S, Brechbiel M, Wiener EC. 2002. Biodistribution of a 153 Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest Radiol 37:199-204.
132. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. 2001. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magma 12:104-113.
133. Konda SD, Aref M, Brechbiel M, Wiener EC. 2000. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: Work in progress. Invest Radiol 35:50-57.
134. Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, Yang ZF, Waters DJ, Snyder PW, Low PS, Welch MJ, Green MA. 2003. Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor- targeted PET radiopharmaceuticals. Nucl Med Biol 30:725-731.
135. Antohe F, Radulescu L, Puchianu E, Kennedy MD, Low PS, Simionescu M. 2005. Increased uptake of folate conjugates by activated macrophages in experimental hyperlipemia. Cell Tissue Res 320:277-285.
136. Chen WT, Mahmood U, Weissleder R, Tung CH. 2005. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res Ther 7:R310-R317.